THE SAFETY OF ORAL-CONTRACEPTIVES - EPIDEMIOLOGIC INSIGHTS FROM THE 1ST 30 YEARS

被引:36
作者
GRIMES, DA [1 ]
机构
[1] UNIV SO CALIF, DEPT OBSTET & GYNECOL, LOS ANGELES, CA 90089 USA
关键词
EPIDEMIOLOGIC STUDIES; SAFETY; BREAST CANCER; OVARIAN CANCER;
D O I
10.1016/0002-9378(92)91394-P
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Because oral contraceptives are used by tens of millions of healthy women, their safety for short-term and long-term use is an important issue that has been examined in a large number of epidemiologic studies. These studies have become more rigorous and have increased in size and analytic sophistication over the years. Although breast cancer remains the most important safety concern, the bulk of recent data suggests that oral contraceptives have no overall impact on a woman's risk of developing this disease, The results are less clear on the risk of cervical cancer and its precursors because of methodologic problems. However, the newer oral contraceptive formulations no longer appear to be associated with an increased risk of myocardial infarction or stroke.
引用
收藏
页码:1950 / 1954
页数:5
相关论文
共 35 条
[1]  
ADAMS MR, 1987, FERTIL STERIL, V47, P1010
[2]  
[Anonymous], 1987, JAMA, V257, P796
[3]  
BERAL V, 1988, LANCET, V2, P1331
[4]  
BRACKEN MB, 1990, FERTIL STERIL, V53, P21
[5]   PHASIC CONTRACEPTIVE PILLS AND FUNCTIONAL OVARIAN CYSTS [J].
CAILLOUETTE, JC ;
KOEHLER, AL .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 156 (06) :1538-1542
[6]  
Cancer and Steroid Hormone Study Investigators, 1986, NEW ENGL J MED, V315, P405, DOI 10.1056/NEJM198608143150701
[7]  
Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development, 1987, N Engl J Med, V316, P650
[8]  
CHILVERS C, 1989, LANCET, V1, P973
[9]   RISK-FACTORS FOR ACUTE MYOCARDIAL-INFARCTION IN WOMEN - EVIDENCE FROM THE ROYAL-COLLEGE-OF-GENERAL-PRACTITIONERS ORAL CONTRACEPTION STUDY [J].
CROFT, P ;
HANNAFORD, PC .
BRITISH MEDICAL JOURNAL, 1989, 298 (6667) :165-168
[10]  
ENGEL HJ, 1983, EUR HEART J, V4, P1